SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending due to its recent inclusion in the S&P MidCap 400 index, sparking anticipation of significant institutional buying. The community is actively discussing the company's strong financial position and its strategic pivot into Agentic AI orchestration, with many viewing it as an undervalued leader in the expanding automation sector despite ongoing debates about recent insider selling.

flyExclusive, Inc. engages in owning and operating jet aircraft for private jet passengers. It manages all aspects of the customer experience, in-house maintenance, repair, and overhaul services, including paint, interiors, and avionics capabilities. The company was founded by Thomas James Segrave, Jr. in 2015 and is headquartered in Kinston, NC.

flyExclusive Inc. - Ordinary Shares - Class A

flyExclusive (FLYX) is captivating market attention after being named an authorized Starlink Aviation dealer, signaling its entry into providing high-speed in-flight connectivity for private jets. This development has sparked extensive community discussion about potential short squeezes, massive trading volume, and the strategic expansion into MRO services. Traders are now evaluating whether this aerospace collaboration can sustain its impressive momentum amidst widespread bullish sentiment and ongoing volatility.

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

Aclarion Inc

Aclarion Inc. (ACON) is gaining significant traction following its corporate outlook, highlighting triple-digit growth for its AI back pain platform, a debt-free balance sheet with substantial cash, and expanding commercial reach. The community is actively debating the stock's exceptionally low share float and high cash-per-share value, anticipating a potential short squeeze and sustained upward momentum. However, some market participants express caution regarding historical volatility and perceived manipulation as volume surges around key price points.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending amid a recent announcement regarding the conversion of convertible debt to equity, prompting intense and divided community discussion. Many traders are actively anticipating a massive short squeeze, citing high cost-to-borrow and limited share availability, with expectations of significant price appreciation. Conversely, others express caution, highlighting potential dilution and the stock's inherent volatility as key concerns, reflecting a speculative market battle.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after receiving positive FDA feedback, confirming its sonelokimab therapy can proceed with a Biologics License Application for hidradenitis suppurativa without additional clinical trials. The community is actively discussing the potential for significant analyst price target upgrades and renewed buyout speculation, with many anticipating a substantial increase from current levels. Despite volatile trading, investors see this de-risked regulatory pathway as a strong catalyst for future appreciation, especially with an Investor Day announced for February.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is generating significant buzz due to its aggressive pipeline expansion, highlighted by ongoing acquisition talks for promising biotechs like Revolution Medicines and its recent purchase of Cidara Therapeutics for an innovative flu treatment. The community sees these strategic moves, alongside positive data for new drugs like its oral cholesterol inhibitor and bladder cancer combo therapy, as Merck proactively addressing its impending Keytruda patent cliff. Investors are closely watching how these efforts position the pharmaceutical giant for sustained future growth.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

General Motors is trending as it initiates a substantial EV-related writedown and a strategic pivot from aggressive electric vehicle expansion amid cooling market demand. This move is being interpreted by the community as a pragmatic "EV demand reset," with discussions highlighting the company's renewed capital discipline and recent analyst upgrades that are tempering concerns over job cuts and controversial software changes.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

Serve Robotics is trending amid reports of potential government support for the robotics industry, including discussions around an executive order, alongside recent endorsements from prominent industry leaders. The community is actively discussing the company's accelerating deployment of autonomous delivery robots, strategic partnerships for last-mile logistics, and its position in the "physical AI" sector, fueling optimism for its long-term growth trajectory.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending after experiencing a multi-day pullback, with investors keenly debating whether the stock is ripe for a bounce due to oversold technicals. While many anticipate a rebound, others express caution, highlighting a perceived lack of immediate AI catalysts compared to peers and Apple's recent market capitalization shift behind Alphabet. This dynamic has created a split in community sentiment, ranging from aggressive dip-buying to continued bearishness.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending due to recently updated revenue guidance for DefenCath extending into 2026 and 2027, which has unfortunately overshadowed the release of strong real-world evidence data for the product and its ongoing diversification through the Melinta acquisition. The community is sharply divided, with many expressing deep disappointment and accusations of mismanagement, while others view the resulting market reaction as an overdone sell-off and a significant buying opportunity for the company's long-term potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>MannKind is now eyeing a potential approval of its Afrezza inhalation powder for children and adolescents living with type 1 or type 2 diabetes.</li><li>H.C. Wainwright reiterated a ‘Buy’ rating on MannKind with an $11 price target after the company’s update.</li><li>The firm said it is positive on MannKind's outlook over the next two years, saying "very little value is ascribed to the multiple tailwinds that could be validated in 2026."</li></ul>MannKind Corporation (MNKD) on Thursday said that it expects two high potential launches going into 2026, driving investor optimism and sending shares up 2%.&nbsp; “With two high-potential launches on the horizon, 2026 is shaping up to be a catalyst-rich year that positions MannKind for long-term value creation,” CEO Michael Castagna<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/08/3215359/29517/en/MannKind-Provides-Business-Updates-and-2026-Growth-Drivers.html"> said,</a> while adding that the company closed 2025 “on a high note” with its acquisition of scPharmaceuticals.<h2 class="st-heading-2">MannKind’s Potential Launches</h2>MannKind is now eyeing a potential approval of its Afrezza inhalation powder for children and adolescents living with type 1 or type 2 diabetes. The U.S. Food and Drug Administration is expected to rule on the application by May 29 and if approved, it would be the first needle-free insulin option for pediatric patients in over 100 years of insulin therapy, the company said.The company is also eyeing approval for its FUROSCIX ReadyFlow Autoinjector, developed to deliver a subcutaneous furosemide injection in under 10 seconds as an investigational alternative to the FDA-approved FUROSCIX On-body Infusor. Furosemide is used for treatment of edema in adult patients with chronic heart failure (CHF) or chronic kidney disease (CKD).<h2 class="st-heading-2">Analyst Weighs In</h2>H.C. Wainwright reiterated a ‘Buy’ rating on MannKind with an $11 price target after the company’s update. The price target represents a potential upside of about 88% from the stock's closing price on Wednesday.&nbsp;The firm said it is positive on MannKind's outlook over the next two years, saying "very little value is ascribed to the multiple tailwinds that could be validated in 2026."<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around MNKD shares jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels.A Stocktwits user dismissed the company’s Thursday update as “another pump and dump.”<stembedurl>https://www.stocktwits.com/Kool_Aid_Mann/message/641251643</stembedurl><a href="https://stocktwits.com/symbol/MNKD">MNKD stock</a> has dropped 3% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ford-stock-rallies-on-piper-sandler-upgrade-plans-to-launch-autonomous-driving-on-30000-ev/cmUbiTNR45X">Ford Stock Rallies On Piper Sandler Upgrade, Plans To Launch Autonomous Driving On $30,000 EV</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mannkind Corp and the company's inhalable insulin product. Company employee demonstrating how the device is used. (Photo by Lawrence K. Ho/Los Angeles Times via Getty Images)

MannKind Rallies On Optimism Of Two Imminent Product Launches: Analyst Sees ‘Multiple Headwinds’ For Stock In 2026

The company’s CEO Michael Castagna said that with two high-potential launches on the horizon, 2026 is shaping up to be a catalyst-rich year that positions MannKind for long-term value creation. 

Equity

MannKind (NASDAQ:MNKD) Reaches New 52-Week High - What's Next?

MannKind (NASDAQ:MNKD) Hits New 12-Month High - Here's Why...

Voya Investment Management LLC Sells 480,182 Shares of MannKind Corporation $MNKD

Voya Investment Management LLC cut its holdings in MannKind Corporation (NASDAQ:MNKD - Free Report) by 89.7% in the third quarter, according to its most recent Form 13F filing with the Securities and...

Calamos Advisors LLC Acquires New Position in MannKind Corporation $MNKD

Calamos Advisors LLC acquired a new stake in shares of MannKind Corporation (NASDAQ:MNKD - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange...

180 Wealth Advisors LLC Increases Stock Position in MannKind Corporation $MNKD

180 Wealth Advisors LLC lifted its position in shares of MannKind Corporation (NASDAQ:MNKD - Free Report) by 11.2% during the third quarter, according to the company in its most recent filing with...

MannKind (NASDAQ:MNKD) Share Price Passes Above Two Hundred Day Moving Average - Here's Why

MannKind (NASDAQ:MNKD) Stock Passes Above Two Hundred Day Moving Average - Here's What Happened...

Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares?

Key PointsCEO Michael Castagna sold 65,804 shares on Dec. 17, 2025, for a total value of approximately ~$395,482 at a weighted average price around $6.01 per share...

<ul class="summary-bullets"><li>The FDA expanded Furoscix use to certain pediatric patients.</li><li>MannKind received five new U.S. patents supporting its ReadyFlow autoinjector, which is still under FDA review.</li><li>The FDA is expected to decide on the ReadyFlow application by July 26, 2026.</li></ul>MannKind Corp (MNKD) shares fell on Tuesday even as the company announced regulatory and patent updates tied to its&nbsp;Furoscix drug, which is used to treat fluid buildup in people with heart failure and kidney disease.At the time of writing, the stock fell 1.4% to $5.91.<h2 class="st-heading-2">Furoscix Gets Pediatric Approval</h2>The company said the U.S. Food and Drug Administration (FDA) approved wider use of&nbsp;Furoscix to include certain pediatric patients who weigh at least 43 kilograms. The drug was previously approved only for adults with fluid buildup caused by chronic heart failure or chronic kidney disease.The company’s chief medical officer said the approval makes&nbsp;Furoscix available to a limited pediatric group and provides an option for treatment outside the hospital for patients who meet the weight requirement.<h2 class="st-heading-2">Patents Support ReadyFlow Autoinjector</h2>MannKind also said it received five new U.S. patents related to its ReadyFlow autoinjector, a device under FDA review that is designed to deliver furosemide in seconds rather than hours.The patents cover the drug formulation and methods of treatment and could provide protection through 2040 if the product is approved. The company said the patents would be listed in the FDA’s Orange Book upon approval.ReadyFlow is based on technology developed by scPharmaceuticals, which MannKind acquired in August. Before the acquisition, scPharmaceuticals reported positive study results showing that the autoinjector delivered furosemide at levels comparable to intravenous dosing. In that study, patients had similar fluid removal results to IV treatment, reported little to no injection pain, and experienced side effects consistent with standard furosemide use.The company reiterated that the FDA is reviewing its application for ReadyFlow for use in adults with heart failure or kidney disease, with a decision expected by July 26, 2026.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for MannKind was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img style="aspect-ratio:970/141;" src="https://news.stocktwits-cdn.com/mnkd_ss_png_2d06a45896.webp" alt="mnkd ss.png" width="970" height="141"><figcaption>MNKD sentiment and message volume as of December 23| Source: Stocktwits</figcaption></figure>One user said the pediatric approval carries limited commercial impact but signals regulatory comfort with&nbsp;Furoscix, which could be supportive ahead of the FDA’s July 2026 decision on the ReadyFlow autoinjector.<stembedurl>https://stocktwits.com/kevinmik/message/639971814</stembedurl>Another retail investor questioned the timing of the announcement, noting it was released just ahead of the Christmas holiday when market activity is typically thin.<stembedurl>https://stocktwits.com/ChillyMutt/message/639959660</stembedurl><a href="https://stocktwits.com/symbol/MNKD">MannKind’s stock</a> has declined 0.9% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

MannKind’s stock has declined 0.9% so far in 2025. (Photo credit: Getty Images)

MannKind Stock Slips Despite FDA Clearing Pediatric Use Of Heart Failure Drug — What’s Spooking Investors?

Shares fell as investors flagged limited commercial impact from the pediatric approval and questioned the timing of the announcement during thin holiday trading.

Michael Castagna Sells 65,804 Shares of MannKind (NASDAQ:MNKD) Stock

MannKind Corporation (NASDAQ:MNKD - Get Free Report) CEO Michael Castagna sold 65,804 shares of the business's stock in a transaction that occurred on Wednesday, December 17th. The shares were sold...

Insider Selling: MannKind (NASDAQ:MNKD) CEO Sells 20,806 Shares of Stock

MannKind Corporation (NASDAQ:MNKD - Get Free Report) CEO Michael Castagna sold 20,806 shares of the stock in a transaction on Friday, December 12th. The stock was sold at an average price of $6.00...

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

SpaceX

Discord

OpenAI

Other - Comment Below

A few major private companies are being discussed as potential IPO candidates in 2026 — including SpaceX, Discord, Databricks, OpenAI, Anthropic, and Deel. IPO timelines can shift, but if one of these listings happens this year, which are you most excited to watch?

Which Potential 2026 IPO Are You Most Excited For?

Stocktwits

Stocktwits Polls

Speculation is rampant about United Therapeutics acquiring MannKind, with detailed financial models showing how owning Tyvaso DPI outright could be more cost-effective than current royalty payments.

MannKind announced record-setting net revenue surpassing $100 million for the fourth quarter, surprising analysts and suggesting significant growth.

Investors are keenly watching multiple upcoming FDA PDUFA dates in 2026 for Afrezza label expansion and FUROSCIX, signaling a catalyst-rich year.

Traders voice frustration over persistent short-selling, pump-and-dump patterns, and perceived market manipulation that hinders sustained upward movement after rallies.

Strong criticisms continue regarding current leadership's competence, strategic direction, and perceived failure to maximize shareholder value.

Current Price	$6.02
Prev Close	$5.85
Open	$5.90
Dividend Yield	0.00%
50-Day Moving Average	$5.56
Beta	0.87
Avg. Volume	3.39M
PE Ratio	62.04

52-Week High	$6.32
52-Week Low	$3.38
Market Capitalization	$1.8B
EPS (Annual)	$0.0972
Price to Book	-40.31
Revenue Per Employee	$701,484.03
Enterprise Value/EBITDA	N/A

MNKD
Mannkind Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MNKD News

MNKDMannkind Corp